CHINA BIOLOGIC PRODUCTS, INC. (NASDAQ:CBPO) Files An 8-K Regulation FD Disclosure
ITEM 7.01 REGULATION FD DISCLOSURE.
On January 4, 2017, China Biologic Products, Inc. (the Company)
announced that the Company will participate in the 35th Annual
J.P. Morgan Healthcare Conference, to be held at the Westin St.
Francis Hotel, San Francisco, California, January 9-12, 2017. Mr.
David Gao, Chairman and Chief Executive Officer, Mr. Ming Yang,
Chief Financial Officer, and Mr. Ming Yin, Senior Vice President
of the Company, will meet with investors at the event. A copy of
the press release is attached as Exhibit 99.1 to this current
report and is incorporated herein by reference.
The materials that the Companys management plans to use at the
conference are available on the Companys website,
www.chinabiologic.com, and are being furnished as Exhibit 99.2 to
this current report.
The information contained in this report, including Exhibits 99.1
and 99.2, shall not be deemed to be filed for purposes of Section
18 of the Securities Exchange Act of 1934, as amended (Exchange
Act), or otherwise subject to the liabilities of that section,
nor shall such information be deemed incorporated by reference in
any filing under the Securities Act of 1933, as amended (the
Securities Act), or the Exchange Act, except as shall be
expressly set forth by specific reference in such a filing.
Safe Harbor Statements
Certain statements contained in the materials furnished with this
current report contain forward-looking statements, including
statements about the business outlook, strategy and market
opportunity of the Company, and statements that may suggest
trends for its business. Such forward-looking statements can be
identified by the use of forward-looking terminology such as
anticipate, believe, could, estimate, expect, intend, may, plan,
potential, should, will, would, and similar expressions, or the
negatives thereof. These statements are individually and
collectively forward-looking statements within the meaning of
Section 27A of the Securities Act and Section 21E of the Exchange
Act. These forward-looking statements are made only as of the
date of the materials and are based on estimates and information
available to the Company at the time of the materials. These
statements are not guarantees of future performance and are
subject to certain risks, uncertainties and assumptions that are
difficult to predict and may be beyond the Companys control.
Therefore, the Company cautions that actual results may differ
materially from those set forth in any forward-looking statements
herein as a result of a variety of factors, including, without
limitation potential delay or failure to complete the clinical
trials for new products, potential delay or failure to complete
construction of new collection facilities, potential inability to
pass government inspection and certification process for new
collection facilities, potential inability to achieve the
designed collection capacities at the new collection facilities,
potential inability to achieve the expected operating and
financial performance, potential inability to find alternative
sources of plasma, potential inability to increase production at
permitted sites, potential inability to mitigate the financial
consequences of a temporarily reduced raw plasma supply through
cost cutting or other efficiencies, and potential additional
regulatory restrictions on its operations and those additional
risks and uncertainties discussed in the Companys periodic
reports that are filed with the SEC and available on its website
(http://www.sec.gov). In light of these risks and uncertainties,
there can be no assurance that the forward-looking statements
made in the materials will in fact be realized. Any
forward-looking statements and projections made by others in the
materials are not adopted by the Company and the Company is not
responsible for the forward-looking statements and projections of
others. Except as otherwise required by applicable securities
laws, the Company disclaims any intention or obligation to
publicly update or revise forward-looking statements, whether as
a result of new information, future events or otherwise.
ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS.
|
Exhibit Number |
Description |
|
| 99.1 | Press release issued by the Company dated January 4, 2017 | |
| 99.2 |
China Biologic Products, Inc. Conference Materials (January 2017) |
About CHINA BIOLOGIC PRODUCTS, INC. (NASDAQ:CBPO)
China Biologic Products, Inc. (China Biologic) is a biopharmaceutical company. The Company is principally engaged in the research, development, manufacturing and sales of human plasma-based biopharmaceutical products in China. It operates in the manufacture and sales of human plasma products segment. It has a product portfolio with over 20 various dosage forms of plasma products and other biopharmaceutical products across over nine categories. Its principal products are human albumin and immunoglobulin for intravenous injection (IVIG). China Biologic operates its business through approximately two subsidiaries, namely, Shandong Taibang Biological Products Co. Ltd. and Guizhou Taibang Biological Products Co., Ltd. The Company also holds an interest in Xi’an Huitian Blood Products Co., Ltd., a plasma products company. Its products also include Human rabies immunoglobulin, Human tetanus immunoglobulin, Placenta polypeptide, Factor VIII and Human prothrombin complex concentrate. CHINA BIOLOGIC PRODUCTS, INC. (NASDAQ:CBPO) Recent Trading Information
CHINA BIOLOGIC PRODUCTS, INC. (NASDAQ:CBPO) closed its last trading session down -0.44 at 107.70 with 89,843 shares trading hands.